The most studied immunobiologicals for EGPA, also known as Churg-Strauss syndrome, are the drugs that act on IL-5, either directly (mepolizumab) or through its receptor (benralizumab).64, 65, 66, 67 It is worth mentioning that, to date, mepolizumab is the only one that has been approved by the regulatory agencies (FDA, EMA and ANVISA) for EGPA treatment. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.